Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Shares Outstanding (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Shares Outstanding for 5 consecutive years, with $795.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.57% to $795.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $795.7 million through Dec 2025, up 2.57% year-over-year, with the annual reading at $795.7 million for FY2025, 2.57% up from the prior year.
  • Shares Outstanding for Q4 2025 was $795.7 million at Mereo BioPharma, roughly flat from $795.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $795.7 million in Q4 2025, with the low at $1.0 million in Q2 2023.
  • Average Shares Outstanding over 4 years is $693.7 million, with a median of $773.7 million recorded in 2024.
  • The sharpest move saw Shares Outstanding skyrocketed 76.16% in 2021, then grew 2.57% in 2025.
  • Over 4 years, Shares Outstanding stood at $788.5 million in 2021, then decreased by 11.07% to $701.2 million in 2023, then grew by 10.63% to $775.7 million in 2024, then increased by 2.57% to $795.7 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $795.7 million, $795.5 million, and $795.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.